Antiplatelet Drug

Antiplatelet Drug - most related articles:

- 4 drugs accounted for two thirds of emergency hospitalizations in US - 5
- FDA will review Daiichi Sankyo, Lilly drug Prasugrel for heart attack - 4.2
- Aspirin resistance increases heart attack, stroke risk - 2.7
- Champion clinical trial program of cangrelor discontinued - 2.2
- Gene variant linked to effectiveness of plavix - 2.2
- Prasugrel cuts risk of stent-related clots - 2.1

Antiplatelet Drug articles

Gene variant linked to effectiveness of plavix
Patients with a certain genetic variation and who received the antiplatelet drug clopidogrel -- Plavix -- had a decreased platelet response to treatment, revealed by researchers.

Prasugrel cuts risk of stent-related clots
The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) - a major concern for physicians and patients with potentially fatal consequences - in patients who received a stent as compared to standard therapy with clopidogrel (Plavix) plus aspirin, according to a stent analysis from the head-to-head TRITON-TIMI 38 trial.

2 Antiplatelet Drug articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.16